Skip to Content
Merck
  • Aberrant cortical development is driven by impaired cell cycle and translational control in a DDX3X syndrome model.

Aberrant cortical development is driven by impaired cell cycle and translational control in a DDX3X syndrome model.

eLife (2022-06-29)
Mariah L Hoye, Lorenzo Calviello, Abigail J Poff, Nna-Emeka Ejimogu, Carly R Newman, Maya D Montgomery, Jianhong Ou, Stephen N Floor, Debra L Silver
ABSTRACT

Mutations in the RNA helicase, DDX3X, are a leading cause of Intellectual Disability and present as DDX3X syndrome, a neurodevelopmental disorder associated with cortical malformations and autism. Yet, the cellular and molecular mechanisms by which DDX3X controls cortical development are largely unknown. Here, using a mouse model of Ddx3x loss-of-function we demonstrate that DDX3X directs translational and cell cycle control of neural progenitors, which underlies precise corticogenesis. First, we show brain development is sensitive to Ddx3x dosage; complete Ddx3x loss from neural progenitors causes microcephaly in females, whereas hemizygous males and heterozygous females show reduced neurogenesis without marked microcephaly. In addition, Ddx3x loss is sexually dimorphic, as its paralog, Ddx3y, compensates for Ddx3x in the developing male neocortex. Using live imaging of progenitors, we show that DDX3X promotes neuronal generation by regulating both cell cycle duration and neurogenic divisions. Finally, we use ribosome profiling in vivo to discover the repertoire of translated transcripts in neural progenitors, including those which are DDX3X-dependent and essential for neurogenesis. Our study reveals invaluable new insights into the etiology of DDX3X syndrome, implicating dysregulated progenitor cell cycle dynamics and translation as pathogenic mechanisms.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-DDX3X antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution